Floatz logo

Azacitidine

Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication

French Innovative Leukemia OrganisationSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Cytarabine
First Affiliated Hospital of Zhejiang University
Phase 3BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
Daunomycin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
xy0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 3BB

View all 21 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Active
BBB
Indicative · Phase 2
73 / 100
View asset →
acute erythroid leukemiaActive
BB
Indicative · Phase 2
71 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BB
Indicative · Phase 2
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →